Sotorasib – an inhibitor of KRAS p.G12c mutation in advanced non-small cell carcinoma: A narrative drug review

The KRAS p.G12C mutation occurs in seen in 13% of non-small cell lung cancers (NSCLCs) and in approximately 1%–3% of colorectal and other cancers. Until the last decade, there were no approved therapies for targeting the KRAS mutation, but recently, drugs targeting the mutation have been discovered....

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Amit Kumar Agrawal, Ramya Pragya, Amit Choudhary, Anuj Gupta, Kuraparthy Sambasivaiah, Bal Krishna Mishra, Satvik Khaddar, Akhil Kapoor
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wolters Kluwer Medknow Publications 2021-01-01
סדרה:	Cancer Research, Statistics, and Treatment
נושאים:	non-small cell lung cancer sotorasib kras g12c precision medicine targeted
גישה מקוונת:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2021;volume=4;issue=3;spage=524;epage=528;aulast=Agrawal
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!